Avzivi
Bevacizumab biosimilar developed by Bio-Thera Solutions, development code BAT1706. Reference product Avastin.
About Avzivi
Avzivi is the bevacizumab developed by Bio-Thera Solutions of China and sold by Sandoz. The United States approved it in December 2023 and Europe in July 2024, where the licence is held through a representative company on Bio-Thera's behalf. It was one of the first Chinese-developed antibodies approved in both markets.
Status by market
United States · Avzivi
US Food and Drug AdministrationApprovedEuropean Union · Avzivi
European Medicines Agency and European CommissionApprovedUnited Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Avzivi holds an approval, these are the other bevacizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| FDA | 5 | Amgen (Mvasi), Biocon Biologics (Jobevne / Abevmy / Krabeva), Celltrion (Vegzelma), Pfizer (Zirabev), mAbxience (Alymsys / Oyavas) |
| EMA | 6 | Amgen (Mvasi), Biocon Biologics (Jobevne / Abevmy / Krabeva), Celltrion (Vegzelma), Pfizer (Zirabev), Samsung Bioepis (Aybintio), mAbxience (Alymsys / Oyavas) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Bio-Thera Solutions: Starjemza, Tofidence / Tocilizumab STADA.
Chronology
- FDADec 2023Approved by FDA as Avzivi
- EMAJul 2024Authorised by the European Commission as Avzivi
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant